The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: A single-institution real-life study
JAAD Case Rep. 2023 Nov 2:43:1-3.
doi: 10.1016/j.jdcr.2023.09.041.
eCollection 2024 Jan.